Sign In

What's New

Apr 24
Data presented at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of...
Apr 24
A new study presented at The International Liver Congress 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma...
Apr 24
The main drugs used to treat alcoholic hepatitis are not effective at increasing patients' survival, a major study has found.

Member Spotlight

Uri Lopatin, MD

Dr. Uri Lopatin is a co-founder and the Chief Medical Officer and VP R&D for Assembly Pharmaceuticals, Inc.